AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03058705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate HCL
Description: Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
Study NCT03058705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Fluorescence (NIRF)
Description: NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
Study NCT01684943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiplex pharmacokinetic profiling
Study NCT00553930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and Ribavirin
Description: All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
Study NCT00553930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2a and Ribavirin
Description: Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of >= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
Study NCT01684943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous insulin monitoring
Study NCT00596817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, daily, orally
Study NCT00596817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally
Study NCT02924168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Radial Shockwave
Description: Four weekly sessions of active radial shockwave treatment.
Study NCT02924168 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Radial Shockwave
Description: Four weekly sessions of sham radial shockwave treatment.
Study NCT01989325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, proteasome inhibitor; intravenous
Description: multiple dose, single schedule
Study NCT01989325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib, KSP(Eg5) inhibitor; intravenous
Description: multiple dose, single schedule
Study NCT01989325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, steroid; oral or intravenous
Description: as indicated, per the carfilzomib prescribing information
Study NCT01989325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: standard of care
Study NCT03683927 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Description: The probiotic (Bacillus clausii) will be administered 4 times a week to the infant
Study NCT03683927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: The placebo group will receive sterile water 4 times a week
Study NCT02625532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Follicular phase
Description: Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
Study NCT02625532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Luteal phase
Description: Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
Study NCT01328977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: teaching
Study NCT01328977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: teaching
Study NCT00842920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 60 mg
Description: 60 mg once daily
Study NCT00842920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet once daily
Study NCT00842920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: 20 mg once daily
Study NCT01022320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Pharyngoplasty
Description: surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
Study NCT02385838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-CNL
Description: The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
Study NCT02385838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTL
Description: The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
Study NCT02385838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDA
Description: The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
Study NCT02385838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tick
Description: The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
Study NCT02451774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline Plus Chemotherapy
Description: Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
Study NCT02451774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Plus Chemotherapy
Description: Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
Study NCT03079141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment.
Study NCT03079141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment.
Study NCT04141501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: single dose of psilocybin (25mg). orally in form of a capsule
Study NCT04141501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: single dose of mannitol (100%)
Study NCT02914704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-HIFU
Description: Treatment of uterine fibroids with MRI-HIFU
Study NCT00667823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Tablet, oral administration, 10 mg dose once daily
Study NCT01492374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-241027
Description: Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
Study NCT01492374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-241027
Description: Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
Study NCT01492374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-241027
Description: Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
Study NCT01492374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-241027
Description: Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
Study NCT03106363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta 9 tetrahydrocannabinol
Description: A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
Study NCT03106363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo delta 9 tetrahydrocannabinol
Description: A single placebo cannabis cigarette (\<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
Study NCT03106363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo delta 9 tetrahydrocannabinol
Description: A single placebo cannabis cigarette (\<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
Study NCT03106363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
Study NCT03106363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo alcohol
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
Study NCT03106363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo alcohol
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
Study NCT04398212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mfERG (multifocal-retinogram)
Description: mfERG will be performed for the students to document the effect of CVS on retina
Study NCT04398212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: mfERG (multifocal-retinogram)
Description: mfERG will be performed for the students to document the effect of CVS on retina
Study NCT03994068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIVO non invasive mapping
Description: non invasive pre-procedural localization of PVC / VT origin
Study NCT02080780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin XL
Description: Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
Study NCT02080780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Diltiazem
Description: 2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
Study NCT03153579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: Lysergic Acid Diethylamide~200ug per os, single dose
Study NCT03153579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to LSD
Study NCT04348383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250 cc every 6 hours for 7 or15 days
Study NCT02266589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
Study NCT01637779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fact sheet
Description: fact sheet about pain management during immunization
Study NCT01637779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact sheet
Description: fact sheet about pain management during immunization
Study NCT04310553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: Patients with locally advanced pancreatic cancer diagnosed by cell / histopathology will receive nano knife treatment if the target lesion is not suitable for surgical resection or the target lesion is suitable for surgical resection but patients give up surgery and choose nano knife combined with chemotherapy. Patients who have not previously received first-line chemotherapy will receive systemic chemotherapy for 4-6 cycles of treatment. Imaging evaluation will be performed every 6-8 weeks (± 7 days) during chemotherapy.
Study NCT02840357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purple Wheat Convenience Bars
Description: Whole grain convenience bars manufactured with purple wheat
Study NCT02840357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Wheat Convenience Bars
Description: Whole grain convenience bars manufactured with ordinary wheat
Study NCT04604080 — intervention group
Intervention type: OTHER
Intervention: service of questionnaire
Description: Respondents will be given a survey form only and after filling this will be collected back
Study NCT02219984 — intervention group
Intervention type: DRUG
Intervention: Anticoagulants
Study NCT00377325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 4 mg/Kg/day; daily; liquid form; 6 months
Study NCT00377325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine
Description: 4 mg/Kg/day; daily; liquid form; 6 months
Study NCT04639674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
Study NCT01367509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Study NCT01648270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.
Study NCT02381522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Pre-conditioning
Study NCT02381522 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Study NCT03752216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria.
Study NCT01676337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message appointment reminder
Description: Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
Study NCT00411593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 g/kg by vein every 3 weeks on day 1 of each cycle.
Study NCT00411593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I.
Study NCT00225433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follitropin beta
Description: Follitropin beta
Study NCT00225433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ganirelix acetate
Description: Ganirelix acetate
Study NCT03703466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT02992990 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bladder tumor biopsy
Description: Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
Study NCT04398537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5mm retraction of clip deployment apparatus.
Description: Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.
Study NCT04398537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No retraction of clip deployment apparatus.
Description: This is one method of standard of care and the clip will be deployed at the biopsy site.
Study NCT03538951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% VDA-1102
Description: 200 mg twice-daily for 12 weeks
Study NCT03538951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% VDA-1102
Description: 200 mg once-daily for 12 weeks
Study NCT02420730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-232411
Description: AGN-232411 topical ophthalmic solution
Study NCT02697851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon 30®
Study NCT02697851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evotaz®
Study NCT00673491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pathways
Description: Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
Study NCT02748109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation + audio biofeedback
Description: Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
Study NCT02748109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
Study NCT03690479 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Florida Probe Straight Tip Probe
Description: Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
Study NCT02420730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-232411 Vehicle
Description: Vehicle for AGN-232411 topical ophthalmic solution.